Abbreviations: DNMT3A, DNA methyltransferase 3 alpha; FLT3-ITD, Fms-like tyrosine kinase 3 receptor-internal tandem duplication; FLT3-TKD, FLT3 tyrosine kinase domain; IDH1/2, Isocitrate dehydrogenase 1/2; NPM1, nucleophosmin 1; NA, no data available; sAML, secondary acute myeloid leukemia; WBC, white blood cells. Summary of the mutation status in DNMT3A, IDH1/2, FLT3 and NPM1, respectively, in 37 patients with sAML. Colored grids indicate the presence of a mutation. Note that these patients, including the mutation status of DNMT3A and IDH1/2 have been previously described.
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Letters to the Editor patients who presented with mutant DNA methyltransferase 3 alpha (DNMT3A) at diagnosis. This led them to assume that mutations in DNMT3A may cause genetic instability and thereby induce FLT3-ITD, ultimately leading to relapse of AML.
We recently described mutations in DNMT3A in 13 of 37 (35%) patients diagnosed with secondary AML (sAML) 2 arising from either myelodysplastic syndromes (MDS) or chronic myeloproliferative neoplasias (MPN). In agreement with Wakita et al., the DNMT3A mutations detected at sAML diagnosis were already present at the time of the precedent MDS/MPN in 10 of 10 (100%) cases, suggesting that mutant DNMT3A is a founder event in the development of sAML. FLT3-ITD is a known progression marker from MDS to AML with low frequencies in the MDS and high frequencies in the secondary leukemia samples, respectively. 3, 4 We, therefore, asked whether the existence of DNMT3A mutations at MDS/MPN diagnosis might be accountable for the accumulation of FLT3-ITD during the clonal evolution to sAML and reanalyzed all 37 sAML specimens described in Fried et al. 2 Screening for mutations in nucleophosmin 1 (NPM1) and the FLT3 tyrosine kinase domain (FLT3-TKD), as well as for the presence of FLT3-ITD was performed as previously described. 5, 6 Informed consent was obtained from all individuals and the study was approved by the institutional review board of the Medical University of Graz, Graz, Austria. Statistical correlation of DNMT3A with FLT3-ITD was calculated by Fisher's exact test using R 2.15.2 (http://www.r-project.org).
We identified FLT3-ITD in 8 of 37 (22%) and point mutations within the FLT3-TKD in 3 of 37 (8%) patients with sAML. Only 3 of 37 (8%) patients exhibited mutations in NPM1, which is less than the frequencies reported in de novo AML. 7 Importantly, FLT3-ITD and DNMT3A mutations occurred independently of each other (P ¼ 0.69; Table 1 ), indicating that the presence of mutant DNMT3A at diagnosis of MDS/MPN does not result in a higher frequency of FLT3-ITD after transformation into sAML. These data raise a couple of issues. First, the fact that different results were reported by Wakita's and our group pinpoint different mechanisms of de novo and secondary leukemogenesis. This assumption is further corroborated by the low frequency of NPM1 mutations observed in our and previous cohorts of sAML patients. 8, 9 Second, as both the groups analyzed a limited number of samples, further investigations are necessary to proof that mutations in DNMT3A in fact cause genetic instability and, in this way, trigger the acquisition of secondary genetic aberrations. Therefore, studies implying next generation sequencing technologies are most appropriate as they allow an unbiased, genome-wide approach for the assessment of both, mutation frequencies, as well as mutational patterns in a wide variety of genes.
Natural history of acute lymphoblastic leukemia in neurofibromatosis type 1 monozygotic twins Leukemia (2013) 27, 1778-1781; doi:10.1038/leu.2013.55
Although the natural history of acute lymphoblastic leukemia (ALL) is clinically silent, identical twin pairs suffering from concordant leukemia provide a unique and tractable model to better understand the clonal evolution of this disease. 1 Recently, genetic studies on ALL have revealed not a linear sequence of mutation acquisition but rather a clonal development model based on complex branching similar to Darwin's evolution trees and natural selection. Indeed, a frequently occurring prenatal first hit is followed by the acquisition of critical and secondary copy number alterations (CNAs) in different subclones, which gain a selective advantage giving rise to leukemia.
